Sanofi Pasteur Sa

Institut National De La Sante Et De La Recherche Medicale

Sanofi Pasteur Inc.

Aventis Pasteur Limited

Other

Bachra Rokbi

Geneviève Renauld-Mongenie

Noëlle Mistretta

Annabelle Bouchardon

Xavier Nassif

Colin Tinsley

Luc Aujame

Monique Moreau

Agnès Perrin

Philippe Talaga

Céline Lafont

Nathalie Guillo

Laurence Quemeneur

Agn&egrave;s Perrin

Jacqueline McCluskey

Nadège Arnaud-barbe

Genevi&egrave;ve Renauld-Mongenie

Ghislaine Maitre-Wilmotte

Pierre-Alexandre Driguez

Vinod Balhara

Denis Speck

Raffaella Iantomasi

Marie-Pierre Kazek-duret

John Shiver

Claude Meric

Olivier Adam

Celine Lafont

Céline Lafont Civat

The present disclosure relates to an immunogenic composition comprising a combination of meningococcal antigens which comprises at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least oneadhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The meningococcal antigens may be from aserogroup B. The combination of antigens provided a broad coverage of bacteria strains. Further, the present disclosure relates to the use of the immunogenic composition in methods for eliciting an immune response.

Meningococcal B recombinant vaccine

The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration &#x3b1; or are exclusively in anomeric configuration &#x3b2; and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.

Immunogenic compositions against

The invention relates to immunogenic compositions comprising at least two(Nm) protein antigens selected from the group consisting of a trypsin-like serine protease auto-transporter antigen such as IgAI P, App or AusI antigen, a NalP antigen and a TbpB antigen. Preferably, the composition of the invention comprises (i) the trypsin-like serine protease auto-transporter antigen and (ii) the NalP antigen and/or TbpB antigen.

[object Object]

The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused byespecially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) ofin particular constituted by a lipid A, an inner core, an &#x3b1; chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain ofthat is capable of expressing such an LOS. The invention also relates to a strain ofof serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an &#x3b1; chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7. The LOSs cited or originating from the mentioned strains may be used as vaccine antigens, especially in multivalent, e.g. divalent compositions, so as to offer protection against the major epiderniological complexes of, especially of serogroup B.

The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused byespecially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) ofin particular constituted by a lipid A, an inner core, an &#x3b1; chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain ofthat is capable of expressing such an LOS. The invention also relates to a strain ofof serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an &#x3b1; chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7. The LOSs cited or originating from the mentioned strains may be used as vaccine antigens, especially in multivalent, e.g. divalent compositions, so as to offer protection against the major epidemiological complexes of, especially of serogroup B.

The invention relates to a culture medium fortype b, characterized in that the source of protein nitrogen is of non-animal origin and comprises at least one plant peptone and in that the heme source consists of protoporphyrin IX. This medium serves in particular for the production of polyribosyl phosphate (PRP) and for the manufacture of a vaccine againsttype b meningitis.

The present invention relates to a method for the production of an overproducingstrain comprising:

The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducingstrains, and also to the immunogenic compositions and the vaccines comprising said capsular polysaccharides.

The invention concerns nucleic acids coding for polypeptides specific of thegenus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.

The present invention relates to a method for the production of an overproducingstrain comprising: (a) culturing astrain on a culture medium M1, M2 or M3, (b) optionally, recovering the strains thus produced from the culture medium, and also to the use of said strains for the production of polysaccharides.

The invention concerns nucleic acids coding for polypeptides specific of the genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.

Growing community of inventors

Lyons, France

Bachra Rokbi